Margolius H.Kallikreins and kinins: molecular characteristics and cellular and tissue responses. Diabetes1996; 45 (suppl 1): S14-S19.
2.
Zisman LSInhibiting tissue angiotensin-converting enzyme: a pound of flesh without the blood. Circulation1998; 98: 2788-2790.
3.
Cleland JG, Morgan K.Inhibition of the renin-angiotensin-aldosterone system in heart failure: new insights from basic research. Curr Opin Cardiol1996; 11: 252-262.
4.
Overlack A.ACE inhibitor-induced cough and bronchospasm. Incidence, mechanisms and management . Drug Saf1996;15: 72-8.
5.
Vleeming W., van Amsterdam JG, Stricker BH, de Wildt DJACE inhibitor-induced angioedema: incidence, prevention and management . Drug Saf1998;18:171-188.
6.
Semple PFPutative mechanisms of cough after treatment with angiotensin-converting enzyme inhibitors.J Hypertens1995; 13 (suppl 3): S17-S21.
7.
Malini PL, Strocchi E., Zanardi M., Milani M.,Ambrosioni E.Thromboxane antagonism and cough induced by angiotensin-converting-enzyme inhibitor. Lancet1997; 350:15-18.
8.
Nussberger J. , Cugno M., Amstutz C., Cicardi M., Pellacani A., Agostoni A.Plasma bradykinin in angioedema. Lancet1998; 351: 1693-1697.
9.
Dell'Italia LJ, Oparil S.Bardykinin in the heart: friend or foe?Circulation1999; 100: 2305-2307.
10.
Gohlke P., Pees C., Unger T.AT2-receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism. Hypertension1998 ; 31: 349-355.
11.
Brown NJ, Ryder D., Gainer JV, Morrow JD, Nadeau J.Differential effects of angiotensin-converting enzyme inhibitors on the vasodepressor and prostacyclin responses to bradykinin. J Pharmacol Exp Ther1996; 279: 703-712.
12.
Bönner G.The role of kinins in the antihypertensive and cardioprotective effects of ACE inhibitors. Drugs1997; 54 (suppl 5):S23-S30.
13.
Hornig B., Kohler C., Drexler H.Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation1997 ; 95:1115-1118.
14.
Gainer JV, Morrow JD, Loveland A., King DJ, Brown NJEffect of bradykinin-receptor blockade on the response to angiotensin-converting enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med1998; 339: 1285-1292.
15.
Bouaziz H., JoulinY., Safar M., Benetos A.Effects of bradykinin B2 receptor antagonism on the hypotensive effects of ACE inhibition. Br J Pharmacol1994; 113:717722.
16.
Cheng CP, Onishi K., Ohte N., Suzuki M., Little WCFunctional effects of endogenous bradykinin in congestive heart failure . J Am Coll Cardiol1998; 31:1679-1686.
17.
Su JB, Barbe F., Crozatier B., Campbell B., Campbell DJ, Hittinger L.Increased bradykinin levels accompany the hemodynamic response to acute inhibition of angiotensin-converting enzyme in dogs with heart failure . J Cardiovasc Pharmacol1999; 34: 700-710.
18.
Davie AP, Dargie HJ, McMurray JJRole of bradykinin in the vasodilator effects of losartan and enalapril in patients with heart failure. Circulation1999 ; 100: 268-273.
19.
Yang X-P., Liu Y-H., Scicli GM,Webb CR, Carretero O.Role of kinins in the cardioprotective effect of preconditioning: study of myocardial ischemia/reperfusion injury in B2 kinin receptor knockout mice and kininogen deficient mice. Hypertension1997; 30 (part 2): 735-740.
20.
Emanueli C. , Maetri R., Corradi D. et al. Dilated and failing cardiomyopathy in bradykinin B2 receptor knockout mice. Circulation1999; 100: 2359-2365.
21.
Benzing T., Fleming I., Blaukat A., Müller-Esterl W., Busse R.Angiotensin-converting enzyme inhibitor ramiprilat interferes with the sequestration of the B2 kinin receptor within the plasma membrane of native endothelial cells. Circulation1999; 99: 2034-2040.
22.
Chung O., UngerT.Angiotensin II receptor blockade and end-organ protection. Am J Hypertens1999;12:150S-156S.
23.
Kokkonen JO , Sarinen J., Kovanen PTAngiotensin II formation in the human heart: an ACE or non-ACE mediated pathway?Ann Med1998; 30 (suppl 1): S9-S13. 3.
24.
Takai S., Jin D., Sakaguchi M., Miyazaki M.Chymase-dependent angiotensin II formation in human vascular tissue . Circulation1999;100: 654-658.
25.
Topol E.ACE inhibitors still the drug of choice for heart failure and more . Lancet1999; 354: 1797.
26.
Neutel JMSafety and efficacy of angiotensin II receptor antagonists. Am J Cardiol1999; 84 (suppl 2A): 13K-17K.
27.
Birkenhager WH, de Leeuw PWNon-peptide angiotensin type 1 receptor antagonists in the treatment of hypertension. J Hypertens1999; 17: 873-881.
28.
Campbell DJEndogenous angiotensin II levels and the mechanism of action of angiotensin-converting enzyme inhibitors and angiotensin receptor type 1 antagonists. Clin Exp Pharmacol Physiol1996; 3 (suppl): S125-S131.
29.
Nora EH, Munzenmaier DH, Hansen-Smith FM, Lombard JH, Greene ASLocalization of the ANG II type II receptor in the microcirculation of skeletal muscle. Am J Physiol1998; 275: H1395-H1403.
30.
Yang BC, Phillips MI, Mohuczy D. et al. Increased angiotensin II type 1 receptor expression in hypercholesterolemic atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol1998;18:1433-1439.
31.
Nakajima M., Hutchinson HG, Fujinaga M. et al. The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the AT1-receptor: gain-of-function study using gene transfer. Proc Natl Acad Sci USA1995; 82: 10663-10667.
32.
Weber MAInterrupting the renin-angiotensin system: the role of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in the treatment of hypertension. Am J Hypertens1999;12:189S-194S.
33.
Tsutsumi Y. , Matsubara H., Masaki H. et al. Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. J Clin Invest1999;104:925-935.
34.
Searles CD, Harrison DGThe interaction of nitric oxide, bradykinin, and the angiotensin II type 2 receptor: lessons learned from transgenic mice. J Clin Invest1999;104:1013-1014.
35.
Cha YJ, Pearson VEAngioedema due to losartan. Ann Pharmacother1999; 33: 936-938.
36.
Mackay FJ, Pearce GL, Mann RDCough and angiotensin II receptor antagonists: cause or confounding?Br J Clin Pharmacol1999; 47: 111-114.
